| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
American College of Clinical Pharmacology:
Symposium III
September 11, 2007 Drug Development and Biotechnology: Update 2007
Cosponsored by The American Association of Pharmaceutical Scientists (AAPS)
8:00 AM - 9:00 AM
Keynote Presentation - "How should we be developing drugs in the 21st Century?"
Hal Barron, M.D., Genentech, Inc., South San Francisco, CA
9:00 AM - 9:45 AM
Preclinical Safety Evaluation of Biopharmaceuticals: Principles vs Practices
Joy A. Cavagnaro, Ph.D., DABT, RAC, Access BIO, LC, Boyce, VA
10:00 - 10:45 AM
The TGN1412 First-In-Man Trial: What Should We Have Learned?
Edward Bernton, M.D., Pathway Pharmacology Consulting , Washington, DC
10:45 AM - 11: 30 AM
Translational PK/PD for First-In-Human Dosing Strategies with Biopharmaceuticals
Mohammad Tabrizi, Ph.D., AstraZeneca R&D, Hayward, CA
11:30 AM - 12:00 PM
Panel Discussion including all speakers
1:30 PM - 2:15 PM
The Two Sides of Specificity: Targeted Therapy with Monoclonal Antibodies and Receptor Tyrosine Kinase Inhibitors
(Lorin K. Roskos, Ph.D., substitute) Gisela Schwab, M.D., Exelixis, Inc., South San Francisco, CA
2:15 PM - 3:00 PM
Biology and Clinical Applications of AMG-531, a New Thrombopoietic Growth Factor
David Kuter, M.D., D.Phil., Massachusetts General Hospital, Boston, MA
3:15 PM - 4:00 PM
FC Engineering of Therapeutic Antibodies
Henry Lowman, Ph.D., Genentech, Inc., South San Francisco, CA
4:00 AM - 4:30 PM
Panel Discussion including all speakers 
Lorin K. Roskos, Ph.D., Executive Director, AstraZeneca R&D, Hayward, CA Hal Barron, M.D., Senior Vice President of Development & Chief Medical Officer, Genentech, Inc., South San Francisco, CA Edward Bernton, M.D., Pathway Pharmacology Consulting, Washington, DC Mohammad Tabrizi, Ph.D., Associate Director, AstraZeneca Pharmaceuticals, LP, Hayward, CA Gisela Schwab, M.D., Senior Vice President and Chief Medical Officer, Exelixis, Inc., South San Francisco, CA David Kuter, M.D., D.Phil., Chief of Hematology , Massachusetts General Hospital, Boston, MA Henry Lowman, Ph.D., Director of Antibody Engineering, Genentech, Inc., South San Francisco, CA Joy A. Cavagnaro, Ph.D., DABT, RAC, President, Access BIO, Access BIO, Boyce, VA
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
